CREO
NEUTRALCreo Medical Announces Investor Presentations Following Preliminary Results
The medical device company will hold investor presentations to discuss its preliminary results for 2024.
Creo Medical Group
10.25GBX
-1.20%
Market Cap
44.34M
Volume
48k
4% of avg
P/E Ratio
-0.03
EPS (TTM)
-2.95
Beta
0.56
Day Range
0.00p - 0.00p
52 Week Range
0.00p10.25p37.20p
10.25p
Upcoming Events
19 May 2025
Investor presentations following 2024 preliminary results
CREO
NEUTRALCreo Medical Group PLC Announces Notice of Results
The medical device company will announce its audited results for the year ended 31 December 2024 on 19 May 2025.
CREO
NEUTRALCreo Medical Group Announces Director Dealings
The healthcare company has disclosed changes in director shareholdings.
CREO
NEUTRALCreo Medical Group Announces Change in Shareholding
The healthcare company has announced a change in its major shareholding structure.
CREO
NEUTRALCreo Medical Grants Options to Directors
The medical device company has granted options over ordinary shares to its executive directors.
CREO
NEUTRALCreo Medical Launches SpydrBlade Flex in UK and Europe
The medical device company has launched its new SpydrBlade Flex product in the UK and Europe, with the first commercial customer being a leading NHS endoscopy unit.
CREO
NEUTRALCreo Medical Appoints Deutsche Numis as Nominated Adviser and Broker
The medical device company has appointed Deutsche Numis as its new Nominated Adviser and sole Broker.
CREO
NEUTRALCreo Medical Completes Strategic Partnership, Receives €30m Cash
The medical device company has completed a strategic partnership, receiving €30m in cash proceeds. However, revenues declined slightly in the period as the business transitions to full commercialisation.
CREO
NEUTRALCreo Medical completes 51% stake sale in European subsidiary
The medical device company has completed the sale of a 51% stake in its European subsidiary, receiving around €30m in cash proceeds to strengthen its balance sheet.
CREO
GOODCreo Medical's Speedboat® Technology Adopted by First Welsh Health Board
The medical device company's innovative Speedboat® technology has been adopted by a Welsh health board, potentially improving patient outcomes and reducing surgical waiting times.